semaglutide gynecomastia case report Spironolactone-Induced Gynecomastia | New England

As we age, our bodies naturally begin reducing the amount of hormones produced like testosterone and estrogen

Table of contents Introduction Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a cornerstone in the therapeutic landscape for Type 2 diabetes mellitus and chronic weight management

(Basically, everything but fat!) In fact, studies suggest that 20% to 50% of the overall weight loss for patients on GLP-1 medications can come from lean body mass

This is surprising, because ketamine prescribed at the right dose does not have the same effect

Common symptoms include anemia, fatigue, weakness, lightheadedness, pale skin, and neurological issues such as tingling or numbness in the hands and feet, muscle weakness, memory problems, poor appetite, and mood changes

"Body composition during weight loss in STEP trials of semaglutide." New England Journal of Medicine , 388(8), 693-705